Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by MoneyTalks22on Aug 10, 2020 10:16am

248 Views

Post# 31386932

Miami Herald article

here are just a couple of Miami Herald comments from the artcile;

"If this drug were to work then how would it not be profitable? it could generate insane profits as the gov can strike a deal with the company and have a reasonable mark up to the patient."

"Algernon Pharma is a small company. Their stock sells for 27 cents a share. Time to buy and help this little company do something to stop Covid patients from dying."

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec